AI Article Synopsis

  • A study on children with congenital heart disease or chronic lung disease found that 200 mg nirsevimab is as safe as palivizumab for RSV prevention.
  • Nirsevimab showed effective serum levels that could help protect healthy infants from severe RSV disease.
  • The results suggest that nirsevimab could also be effective for children at high risk of severe RSV during their second RSV season.

Article Abstract

In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469583PMC
http://dx.doi.org/10.1093/jpids/piad052DOI Listing

Publication Analysis

Top Keywords

rsv season
8
lung disease
8
safety re-dosing
4
re-dosing nirsevimab
4
nirsevimab prior
4
prior rsv
4
season children
4
children heart
4
heart lung
4
disease
4

Similar Publications

Using machine learning to forecast peak health care service demand in real-time during the 2022-23 winter season: A pilot in England, UK.

PLoS One

January 2025

Real-time Syndromic Surveillance Team, Field Services, Health Protection Operations, UK Health Security Agency, Birmingham, United Kingdom.

During winter months, there is increased pressure on health care systems in temperature climates due to seasonal increases in respiratory illnesses. Providing real-time short-term forecasts of the demand for health care services helps managers plan their services. During the Winter of 2022-23 we piloted a new forecasting pipeline, using existing surveillance indicators which are sensitive to increases in respiratory syncytial virus (RSV).

View Article and Find Full Text PDF

Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus.

JAMA Intern Med

January 2025

Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, Washington.

Importance: SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) contribute to many hospitalizations and deaths each year. Understanding relative disease severity can help to inform vaccination guidance.

Objective: To compare disease severity of COVID-19, influenza, and RSV among US veterans.

View Article and Find Full Text PDF

Acute respiratory infections (ARIs) are a leading cause of death in children under five globally. The seasonal trends and profiles of respiratory viruses vary by region and season. Due to limited information and the population's vulnerability, we conducted the hospital-based surveillance of respiratory viruses in Eastern Uttar Pradesh.

View Article and Find Full Text PDF

: Three respiratory syncytial virus (RSV) vaccines have been recently made available for older adults. Understanding the principal characteristics of the first vaccine-takers can pave the way for a successful vaccination campaign. The objective of this study was to explore the sociodemographic and clinical characteristics of the first Italian users of an adjuvanted RSV vaccine and their attitudes towards RSV and vaccination.

View Article and Find Full Text PDF

Respiratory Syncytial Virus (RSV) is a prevalent pathogen of the respiratory tract, posing a significant threat to individuals with compromised immune systems, particularly the elderly and neonates in hospital settings. The primary objective of this study was to identify a specific period within the epidemic season during which healthcare providers can anticipate an increased incidence of RSV infections and characterize the epidemic season in Poland. Molecular biology techniques were employed to diagnose samples at Sanitary Stations and the National Institute of Public Health (NIC) in Warsaw.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!